Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Eagle Pharmaceuticals
(NASDAQ:EGRX)
Intraday
$4.55
0
[0.00%]
After-Hours
$4.55
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$4.55
0
[0.00%]
At close: Apr 22
$4.55
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Eagle Pharmaceuticals Stock (NASDAQ:EGRX)
Eagle Pharmaceuticals Stock (NASDAQ: EGRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 15, 2024
Eagle Pharmaceuticals To Present Additional Data from Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National Conference
Benzinga Newsdesk
-
Apr 15, 2024, 7:25AM
Friday, April 12, 2024
Eagle Pharmaceuticals Announces Receipt Of Notification Of Deficiency From Nasdaq Regarding Requirement To Timely File Annual Report On Form 10-K
Benzinga Newsdesk
-
Apr 12, 2024, 4:09PM
Thursday, January 18, 2024
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
Benzinga Newsdesk
-
Jan 18, 2024, 6:56AM
Wednesday, December 06, 2023
Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City
Benzinga Newsdesk
-
Dec 6, 2023, 4:29PM
Thursday, November 30, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Nov 30, 2023, 4:31PM
Wednesday, November 29, 2023
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Nov 29, 2023, 2:02PM
Why Is Eagle Pharmaceuticals Stock Trading Lower Today?
Vandana Singh
-
Nov 29, 2023, 1:46PM
Eagle Pharmaceuticals shares are trading lower after the company announced it received notification of deficiency from the Nasdaq regarding the requirement to timely file quarterly report on Form 10-Q. Also, Founder, President and CEO Scott Tarriff announced his resignation effective immediately.
Benzinga Newsdesk
-
Nov 29, 2023, 12:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Nov 29, 2023, 12:31PM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Nov 29, 2023, 8:06AM
Eagle Pharmaceuticals Receives Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
Benzinga Newsdesk
-
Nov 29, 2023, 7:36AM
Eagle Pharmaceuticals Says Effective Immediately Scott Tarriff, Founder, President And CEO, Has Announced His Resignation And Retirement; Chairman Michael Graves To Serve As Interim Executive Chairman
Benzinga Newsdesk
-
Nov 29, 2023, 7:32AM
Friday, November 17, 2023
Top 4 Health Care Stocks That Could Blast Off This Quarter
Lisa Levin
-
Nov 17, 2023, 7:26AM
Tuesday, November 14, 2023
Earnings Scheduled For November 14, 2023
Benzinga Insights
-
Nov 14, 2023, 8:23AM
Monday, November 13, 2023
Eagle Pharmaceuticals's Earnings: A Preview
Benzinga Insights
-
Nov 13, 2023, 1:02PM
Thursday, November 09, 2023
Eagle Pharmaceuticals shares are trading lower after the company announced it delayed its Q3 results to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filling its Form 10-Q. Also, it expects to revise its FY23 guidance
Benzinga Newsdesk
-
Nov 9, 2023, 1:22PM
Eagle Pharmaceuticals Delays Q3 2023 Results And Conference Call; Expects to File Its Form-10-Q By Nov. 14, 2023
Benzinga Newsdesk
-
Nov 9, 2023, 8:31AM
Wednesday, November 01, 2023
Board Member at Eagle Pharmaceuticals Exercises Options Worth $128K
Benzinga Insights
-
Nov 1, 2023, 11:01AM
Tuesday, October 24, 2023
Eagle Pharmaceuticals Granted Patent For PEMFEXY
Benzinga Newsdesk
-
Oct 24, 2023, 8:41AM
Monday, October 23, 2023
Eagle Pharmaceuticals Says Granted Unique J-Code And Pass-Through Status For BARHEMSYS From CMS
Benzinga Newsdesk
-
Oct 23, 2023, 6:59AM
Thursday, October 05, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Oct 5, 2023, 1:22PM
Thursday, September 28, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 28, 2023, 2:32PM
Tuesday, September 19, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 19, 2023, 12:50PM
Monday, September 11, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Sep 11, 2023, 1:38PM
Friday, September 08, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 8, 2023, 1:58PM
Tuesday, August 29, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 29, 2023, 2:37PM
Eagle Pharmaceuticals Announced A Type C Meeting With The FDA Agreeing On A Path Forward To Advance The Development Of EA-114 For Breast Cancer In Post-menopausal Women. Eagle Currently Anticipates Filing A New Drug Application For EA-114 In 2024
Benzinga Newsdesk
-
Aug 29, 2023, 6:55AM
Thursday, August 17, 2023
Eagle Pharmaceuticals Reiterates Its Previously Issued Guidance For Fy23, With Adjusted EBITDA Of $78M-$84M And Adjusted EPS Of $4.40-$4.70 Versus Consensus Of $4.34
Benzinga Newsdesk
-
Aug 17, 2023, 6:53AM
Wednesday, August 09, 2023
Piper Sandler Downgrades Eagle Pharmaceuticals to Underweight, Lowers Price Target to $17
Benzinga Newsdesk
-
Aug 9, 2023, 12:12PM
Tuesday, August 08, 2023
Eagle Pharmaceuticals Reiterates FY23 Adjusted EPS Guidance Of $4.40-$4.70 Vs. Consensus Of $4.34
Benzinga Newsdesk
-
Aug 8, 2023, 6:54AM
Eagle Pharmaceuticals Q2 Adjusted EPS $1.18 Beats $1.05 Estimate, Sales $64.65M Beat $59.35M Estimate
Benzinga Newsdesk
-
Aug 8, 2023, 6:52AM
Earnings Scheduled For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 4:48AM
Monday, August 07, 2023
Earnings Outlook For Eagle Pharmaceuticals
Benzinga Insights
-
Aug 7, 2023, 4:02PM
Monday, July 31, 2023
Eagle Pharmaceuticals Boosts 2023 Adjusted EPS Guidance From $4.20-$4.53 To $4.40-$4.70, Consensus $4.26
Benzinga Newsdesk
-
Jul 31, 2023, 6:52AM
Monday, July 24, 2023
Eagle Pharmaceuticals Announced That The First Patient Has Been Randomized In Its Phase 2 Study Of CAL02 For Severe Community-acquired Bacterial Pneumonia; The Plans To Enroll Approximately 276 Patients; First 50% Interim Report Is Expected Around Q1 2024
Benzinga Newsdesk
-
Jul 24, 2023, 6:52AM
Friday, June 16, 2023
Eagle Pharmaceuticals Filing Shows Danaos Corporation Reports 9.99% Passive Stake In Co As Of June 6, 2023
Benzinga Newsdesk
-
Jun 16, 2023, 4:28PM
Thursday, June 15, 2023
Eagle Pharmaceuticals Reaffirms Its FY23 Adjusted EBITDA Guidance Of $74M-$80M, With Adjusted EPS Of $4.20-$4.53 Vs. Consensus Of $4.29
Benzinga Newsdesk
-
Jun 15, 2023, 6:55AM
Wednesday, June 14, 2023
Eagle Pharma Gets FDA Qualified Infectious Disease Product (QIDP) And Fast-Track Designation For CAL02, Providing Five-Year Exclusivity Extension
Benzinga Newsdesk
-
Jun 14, 2023, 6:51AM
Tuesday, June 06, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Jun 6, 2023, 1:54PM
Monday, June 05, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Jun 5, 2023, 12:23PM
Friday, May 19, 2023
Massive Insider Trade At Eagle Pharmaceuticals
Benzinga Insights
-
May 19, 2023, 11:05AM
Tuesday, May 16, 2023
CEO At This Health Care Company Sells $930K of Stock
Benzinga Insights
-
May 16, 2023, 11:03AM
Wednesday, May 10, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
May 10, 2023, 3:12PM
Tuesday, May 09, 2023
Eagle Pharmaceuticals shares are trading lower after the company reported Q1 financial results and reaffirmed guidance.
Benzinga Newsdesk
-
May 9, 2023, 12:17PM
Eagle Pharmaceuticals Reaffirms FY23 Adj. EPS Outlook $4.20 - $4.53 vs. $4.24 Estimate
Benzinga Newsdesk
-
May 9, 2023, 6:53AM
Eagle Pharmaceuticals Q1 Adj. EPS $1.26 Beats $1.05 Estimate, Sales $66.31M Beat $63.29M Estimate
Benzinga Newsdesk
-
May 9, 2023, 6:51AM
Earnings Scheduled For May 9, 2023
Benzinga Insights
-
May 9, 2023, 6:03AM
Monday, May 01, 2023
The Centers For Medicare & Medicaid Services Has Established Product-specific Billing Code For Eagle Pharmaceuticals' Byfavo (Remimazolam), A Short-acting Sedative For Procedures Lasting 30 Minutes Or Less. The J-code Will Be Effective On July 1, 2023
Benzinga Newsdesk
-
May 1, 2023, 6:53AM
Wednesday, April 05, 2023
Eagle Pharmaceuticals Reaches Settlement Agreement With Dr. Reddy's Laboratories Related To BENDEKA (bendamustine hydrochloride); Terms Not Disclosed
Benzinga Newsdesk
-
Apr 5, 2023, 6:54AM
Monday, March 13, 2023
Eagle Pharmaceuticals Sees FY23 Adjusted EPS Of $4.20-$4.53 Vs. Consensus of $4.49
Benzinga Newsdesk
-
Mar 13, 2023, 6:54AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch